Gabapentin Should NOT Be Used for Osteoarthritis in Older Adults
Gabapentin is not recommended for osteoarthritis pain management in older adults, even with normal renal function, as it lacks efficacy for this indication and carries significant safety risks in this population.
Why Gabapentin Should Be Avoided
Lack of Evidence for Efficacy
The most recent high-quality cost-effectiveness analysis 1 from 2023 definitively showed that gabapentin does not provide value in knee osteoarthritis. The study found that usual care without gabapentin resulted in better outcomes (more quality-adjusted life years) and lower costs compared to both targeted and universal gabapentin strategies. Even when researchers optimized assumptions in favor of gabapentin (100% specificity for identifying nociplastic pain and 0% adverse event rate), the cost-effectiveness ratio remained unfavorable at $53,000/QALY.
Significant Safety Concerns in Older Adults
The 2019 AGS Beers Criteria 2 specifically warns against combining gabapentinoids with opioids in older adults due to increased risks. This is particularly relevant since:
- Patients with osteoarthritis are frequently co-prescribed opioids and gabapentinoids 3, creating a dangerous drug-drug interaction
- The risk of gabapentinoid-opioid co-prescription is 29% higher in OA patients compared to controls 3
Gabapentin causes dose-dependent altered mental status in older adults 4:
- High-dose gabapentin (>600 mg/day) increases hospitalization risk for altered mental status by 29% (adjusted RR 1.29)
- This risk exists even at low doses, though it increases with higher dosing
- Mean age in this study was 76 years—typical for OA patients
Additional age-related risks:
- Gabapentin clearance decreases significantly with age 5—from 225 mL/min in patients under 30 to 125 mL/min in those over 70
- This reduced clearance leads to drug accumulation and increased toxicity risk
- Peripheral edema and ataxia increase in incidence with age 5
- Recent evidence shows increased fracture risk with current gabapentinoid use (OR 1.36) 6, particularly concerning given that OA patients already have elevated fracture risk
What SHOULD Be Used Instead
First-Line Treatment
Acetaminophen remains the recommended first-line agent 7:
- Effective for osteoarthritis and low back pain symptoms
- Superior safety profile compared to NSAIDs (no significant GI bleeding, renal effects, or cardiovascular toxicity)
- Maximum safe dose: 4 grams per 24 hours from all sources
- Start with 1,000 mg doses to assess efficacy before escalating to stronger medications
Second-Line Options
If acetaminophen is insufficient:
- Topical or oral NSAIDs (short-term use only in older adults due to GI and renal risks)
- Intra-articular corticosteroid injections for localized joint pain
- Duloxetine showed similar efficacy to gabapentin for OA pain 8 but with earlier onset of action
Critical Clinical Pitfalls
Do not prescribe gabapentin simply because a patient has "nerve-like" pain descriptors—OA pain is primarily nociceptive, not neuropathic, despite occasional nociplastic features
Avoid the gabapentinoid-opioid combination 2—this is explicitly flagged as a potentially inappropriate medication interaction in older adults
Do not assume "normal renal function" means safety—age-related pharmacokinetic changes occur independent of measured creatinine clearance 5
Monitor for early cognitive changes if gabapentin has already been started—confusion, dizziness, and drowsiness are common and dose-dependent 4
The evidence is clear: gabapentin offers no proven benefit for osteoarthritis while exposing older adults to unnecessary risks of altered mental status, falls, fractures, and dangerous drug interactions.